User menu

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Bibliographic reference Coles, Alasdair J ; Twyman, Cary L ; Arnold, Douglas L ; Cohen, Jeffrey A ; Confavreux, Christian ; et. al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.. In: Lancet, Vol. 380, no.9856, p. 1829-39 (2012)
Permanent URL http://hdl.handle.net/2078.1/124398